CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: A case report and review of the literature

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 744-746

  Gopaluni, Srivalli ^a   Perzova, Raiza ^a   Abbott, Lynn ^a   Farah, Ramsey ^a   Shrimpton, Anthony ^a   Hutchison, Robert ^a   Poiesz, Bernard J ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; DENILEUKIN DIFTITOX; EZETIMIBE; INTERFERON; LEVOTHYROXINE; PSORALEN; SIMVASTATIN; STEROID;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; CD8+ T LYMPHOCYTE; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; MALE; MONOTHERAPY; MYCOSIS FUNGOIDES; NEPHRECTOMY; NONHODGKIN LYMPHOMA; PAIN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN INFLAMMATION; SKIN LYMPHOMA; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME; XERODERMA;

ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; AZETIDINES; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; EXANTHEMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOTHYROIDISM; INCIDENTAL FINDINGS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASMS, MULTIPLE PRIMARY; SIMVASTATIN; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES; THYROXINE;

EID: 51449104242     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21231     Document Type: Article

References (38)

1. Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: From Alibert to WHO-EORTC. J Cutan Pathol 2006;33:18-26.
2. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-1988.
3. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999;155:483-492.
4. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-7419.
5. Poiesz B, Dube D, Dube S, et al. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med 2000;342:930-936.
6. Poiesz BJ, Poiesz MJ, Choi D. The human T-cell lymphoma/leukemia viruses. Cancer Invest 2003;21:253-277.
7. Calattini S, Cheralier SA, Duprez R, et al. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retroviral 2005;2:30.
8. Wolfe ND, Heneine W, Carr JK, et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci USA 2005;102:7994-7999.
9. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-1240.
10. Poiesz BJ, Papsidero LP, Ehrlich G, et al. Prevalence of HTLV-I associated T-cell lymphoma. Am J Hematol 2001;66:32-38.
11. Dummer R, Kamarasher J, Kempf W, et al. Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior variant of mycosis fungoides? Arch Dermatol 2002;138:199-203.
12. Magro CM, Crowson AN, Morrison C, et al. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol 2006;125:490-501.
13. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol 2002;29:465-472.
14. Whittam LR, Calonje E, Orchard G, et al. CD8- positive juvenile onset mycosis fungoides, and immunohistochemical and genotypic analysis of six cases. Br J Dermatol 2000;143:1199-1204.
15. Nahass GT, Kraffert CA, Penneys NS. Cutaneous T-cell lymphoma associated with the acquired immunodeficiency symdrome. Arch Dermatol 1991;127:1045-1047.
16. Kaplan MH, Hall WW, Susin M, et al. Syndrome of severe skin disease, eosinophilia and dermatopathic lymphadenopthy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med 1991;91:300-309.
17. Burns MK, Cooper KD. Cutaneous T-cell lymphoma with HIV infection. J Am Acad Dermatol 1993;29:394-399.
18. Guitart J, Variakojis D, Kuzel T, Rosen S. Cutaneous CD8 T cell infiltrates in advanced HIV infection. J Am Acad Dermatol 1999;41:722-727.
19. Urrutia S, Piris MA, Orradre JL, et al. Cytotoxic/suppressor (CD8+, CD4-) cutaneous T-cell lymphoma with aggressive course. Am J Dermatopathol 1990;12:603-606.
20. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: Identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 1990;22:569-577.
21. Fujiwara Y, Abe Y, Kuyama A, et al. CD8+ cutaneous T-cell lymphoma with pagetoid epidermotropism and angiocentric and angiodestructive infiltration. Arch Dermatol 1990;126:801-804.
22. Morzano AV, Ghislanzoni M, Gianelli U, et al. Fatal CD8+ epidermotropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement. Dermatology 2005;211:281-285.
23. Marti RM, Pujol RM, Servitije O, et al. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003;44:59-69.
24. Whittam LR, Calonje E, Orchard G, et al. CD8-positive juvenile onset mycosis fungoides: An immunohistochemical and genotypic analysis of six cases. Br J Dermatol 2000;143:1199-1204.
25. Quarterman MJ, Lesher JL Jr, Davis LS, et al. Rapidly progressive CD8-positive cutaneous T-cell lymphoma with tongue involvement. Am J Dermatopathol 1995;17:287-291.
26. Gelfand JM, Wasik MA, Vittorio C, et al. Progressive epidermotropic CD8+/CD4- primary cutaneous CD30+ lymphoproliferative disorder in a patient with sarcoidosis. J Am Acad Dermatol 2004;51:304-308.
27. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
28. Farol LT, Hymes KB. Bexarotene: A clinical review. Expert Rev Anticancer Ther 2004;4:180-188.
29. Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol 2004;51:25-32.
30. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-593.
31. Foss F. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol 2004;16:421-428.
32. Wong SF. Oral bexarotene in the treatment of cutaneous T-cell lymphoma. Ann Pharmacother 2001;35:1056-1065.
33. Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma results of the phase III clinical trial. J Am Acad Dermatol 2003;49:801-815.
34. Keun YK, Woodruff R, Sangueza O. Response of CD30+ large cell lymphoma of the skin to bexarotene. Leuk Lymphoma 43;1153-1154.
35. Bouwhis SA, Davis MD, el-Azhary RA, et al. Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: Development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005;52:991-996.
36. Guitart J. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006;33:517-520.
37. Vittorio CL, Rook AH, French LE, et al. Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma. BioDrugs 2001;15:431-437.
38. Kreuter A, Altmeyer P. Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sezary syndrome. J Am Acad Dermatol 2005;53:1093-1095.